Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Funding
Funding not disclosed
Founders
Product
Problem
Existing treatments for anxiety and stress disorders, such as SSRIs and benzodiazepines, can have significant drawbacks, including sedation, cognitive impairment, and addiction risks. Many individuals do not experience adequate relief from these treatments, highlighting the need for novel therapeutic options.
Solution
Neuphoria Therapeutics is developing BNC210, a proprietary, orally administered, selective negative allosteric modulator (NAM) of the α7 nicotinic acetylcholine receptor (α7 nAChR) for neuropsychiatric disorders. BNC210 targets glutamatergic hyperactivity in brain regions associated with stress, anxiety, and mood disorders. Clinical trial data suggests that BNC210 offers rapid anti-anxiety and anti-depressive effects without the sedation, memory impairment, or addiction risks associated with current standard-of-care treatments. The company is currently conducting Phase 3 trials for Social Anxiety Disorder (SAD) and advancing clinical programs for Post-Traumatic Stress Disorder (PTSD).
Target Audience
The primary target audience includes individuals suffering from social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD), as well as clinicians seeking safer and more effective treatment options for these conditions.
Features
- BNC210: A selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor
- Oral tablet formulation allowing for "as-needed" or chronic dosing
- Demonstrated rapid anti-anxiety and anti-depressive effects in clinical trials
- Reduced hyperactivity in the amygdala, a brain region linked to heightened anxiety, as observed in fMRI scans
- Potential applications beyond SAD and PTSD, including Generalized Anxiety Disorder (GAD) and panic disorder
- Next-generation α7 NAM program with patented molecules targeting CNS disorders